Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study
J. Kisel (London, United Kingdom), E. Ballard (London, United Kingdom), S. Eui-Sik (London, United Kingdom), N. Hart (London, United Kingdom), S. Srivastava (London, United Kingdom), P. Murphy (London, United Kingdom), P. Marino (London, United Kingdom), S. Kapetanakis (London, United Kingdom), J. Steier (London, United Kingdom)
Source: International Congress 2022 – Clinical problems in pleural and respiratory muscle disorders
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Kisel (London, United Kingdom), E. Ballard (London, United Kingdom), S. Eui-Sik (London, United Kingdom), N. Hart (London, United Kingdom), S. Srivastava (London, United Kingdom), P. Murphy (London, United Kingdom), P. Marino (London, United Kingdom), S. Kapetanakis (London, United Kingdom), J. Steier (London, United Kingdom). Cardioprotective medication in Duchenne muscular dystrophy: a single-centre cohort study. 1088
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|